SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%

Cantor Fitzgerald Maintains Overweight on Reata Pharmaceuticals, Raises Price Target to $275

Cantor Fitzgerald maintains Reata Pharmaceuticals (NASDAQ:RETA) with a Overweight and raises the price target from $270 to $275.

Benzinga · 05/18/2020 15:11

Cantor Fitzgerald maintains Reata Pharmaceuticals (NASDAQ:RETA) with a Overweight and raises the price target from $270 to $275.